Who Is Setting the Price for AI4S?
SVTR statistics cited in a 潮涌AI article, authorized for publication by 36Kr, cover 118 confirmed financing rounds for 175 AI4S companies from September 2025 to September 2026, totaling about $7.5 billion. Isomorphic Labs accounted for $2.1 billion, or 28% of the total, while 13 companies with individual rounds above $100 million captured 73%. The analysis proposes four valuation layers—pipeline, platform, tools and capital—linked respectively to pharmaceutical R&D budgets, computing and laboratory infrastructure costs, software spending and prospective exit buyers. The framework is the analysis's own interpretation, and several reported high-value financings and valuations were still under negotiation.
The framework shifts attention from headline valuations to the buyers, revenue, clinical milestones, infrastructure costs and exit routes that underpin them. It also highlights that financing concentration and unclosed negotiations limit what can be inferred from the figures.

近日,海外AI4S(AI for Science)赛道的资本消息密集落地。无论是OpenAI收购药物研发协调平台Orchestra Bio、Iambic登陆公开市场募资1.5亿美元,还是彭博报道Isomorphic Labs正以约500亿美元估值洽谈50亿美元新融资,以及Mirendil的A轮就拿到10亿美金......
本文来自微信公众号: 潮涌AI ,作者:潮涌AI编辑部
近日,海外AI4S(AI for Science)赛道的资本消息密集落地。
无论是OpenAI收购药物研发协调平台Orchestra Bio、Iambic登陆公开市场募资1.5亿美元,还是彭博报道Isomorphic Labs正以约500亿美元估值洽谈50亿美元新融资,以及Mirendil的A轮就拿到10亿美金……大额融资、巨头并购、IPO退出在年内接连出现,AI4S热度背后的问题是,这些公司究竟凭什么拿到这个价格。
#Isomorphic Labs#Mirendil#Periodic Labs#Lila Sciences#Chai Discovery#Generate Biomedicines#OpenAI#Orchestra Bio#Iambic#NVIDIA#Schrödinger#Insilico Medicine